Invasive Fungal Infections: Problems and Challenges for Developing New Antifungal Compounds

  • Thomas J. Walsh

Abstract

Invasive fungal infections have emerged during the past two decades as important pathogens causing formidable morbidity and mortality in an increasingly diverse and progressively expanding population of immunocompromised patients. Those with the acquired immune deficiency syndrome (AIDS) constitute the most rapidly growing group of patients at risk for life-threatening mycoses, especially cryptococcal meningitis [61, 102], disseminated histoplasmosis [125, 125a], and coccidioidomycosis [13, 50a]. These infections are generally community acquired and often develop as a consequence of reactivation of latent infection. Oropharyngeal and esophageal candidiasis are common infections in approximately one-half of all children and adults with AIDS [118, 118]. Selik et al. described features of the first 30,632 AIDS patients in the United States reported to the Centers for Disease Control [94]. Esophageal candidiasis occurred with similar frequency in both populations, being found in 15.4% of 350 children (age <13 years) with AIDS in comparison to 10.6% of all AIDS patients and 8.5–16.8% of various subpopulations of adults with AIDS.

Keywords

Antifungal Therapy Invasive Aspergillosis Acquire Immune Deficiency Syndrome Invasive Fungal Infection Invasive Candidiasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abrams, D., H. Luber, H. Glueck, and et al. 1985. Disseminated coccidioidomycosis in AIDS.N. Eng. J. Med. 310:986–987.Google Scholar
  2. 2.
    Adamson, P.C., M.G. Rinaldi, P.A. Pizzo, and T.J. Walsh. 1989. Amphotericin B in treatment of Candida cholecystitis. Ped. Infect. Dis. J. 8:408–411.CrossRefGoogle Scholar
  3. 3.
    Anaissie, E., D.P. Kontoyiannis and G. Bodey. 1990. Fusarial hyalohyphomycosis: Clinical spectrum, prognosis, and treatment. 30th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1128.Google Scholar
  4. 4.
    Anaissie, E., and G.P. Bodey. 1989. Nosocomial fungal infections. Old problems and new challenges. Infect. Dis. Clin. N. Amer. 3:867–882.Google Scholar
  5. 5.
    Anaissie, E., H. Kantarjian, J. Ro, and G. Bodey. 1988. The emerging role of Fusarium infections in patients with cancer. Medicine 67:77–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Antman, K., J. Griffin, A. Elias, L. Ryan, S. Cannistra, D. Oette, M. Whitley, E. Frei 3rd, and L. Schnipper. 1988. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N. Eng. J. Med. 319:593–598.CrossRefGoogle Scholar
  7. 7.
    Armstrong, D., 1989. Problems in management of opportunistic fungal infections. Rev. Infect. Dis. 11 (Suppl. 7):S1591.PubMedCrossRefGoogle Scholar
  8. 8.
    Becker, J.M., S. Marcus, J. Tallock, D. Miller, E. Krainer, R. Khare, and F. Naider. 1988. Use of the chitin-synthesis inhibitor nikkomycin to treat disseminated candidiasis in mice. J. Infect. Dis. 147:212–214.CrossRefGoogle Scholar
  9. 9.
    Beck-Sague, G., W. Jarvis, S. Banerjee, D. Culver, R. Gaynes, and T.N.N.I.S. System. 1990. Nosocomial fungal infections in U.S. hospitals, 1980–1990. 30th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1129.Google Scholar
  10. 10.
    Bousgnoux, M.E., C. Hill, D. Moissenet, M.F. DeChauvin, M. Bonnay, I. VicensSprauel, F. Pietri, M. McNeil, L. Kaufman, J. Dupouy-Camet, C. Bohuon, and A. Andremont. 1990. Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis. J. Clin. Microbiol. 28:905–909.Google Scholar
  11. 11.
    Brandt, S., W.P. Peters, K. Waters, S.K. Atwater, J. Kurtzberg, M.J. Borowitz, R.B. Jones, E.J. Shpall, R.C. Bast, Jr., C. J. Gilbert, and D. H. Oette. 1988. Effect of recombinant human granulocyte-macrophage colony stimulating factor on hematopoietic reconstitution after high dose of chemotherapy and autologous bone marrow transplantation. N. Eng. J. Med. 318:869–876.CrossRefGoogle Scholar
  12. 12.
    Bronchud, M., J. Scarffe, N. Thatcher, D. Crowther, L. Souza, N. Alton, N. Testa, and T. Dexter. 1987. Phase IIII study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small-cell lung cancer. Br. J. Cancer. 56:809–813.PubMedCrossRefGoogle Scholar
  13. 13.
    Bronniman, D., R. Adam, J. Galgiani, M. Habib, E. Petersen, B. Porter, and J. Bloom. 1987. Coccidioidomycosis in the acquired immunodeficiency syndrome. Ann. Int. Med. 106:372–379.Google Scholar
  14. 14.
    Brooks, R.G. 1989. Prospective study of Candida endophthalmitis in hospitalized patients with candidemia. Arch. Int. Med. 149:2226–2228Google Scholar
  15. 15.
    Burch, P.A., J.E. Karp, W.G. Merz, J.E. Kuhlman, and E.K. Fishman. 1987. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J. Clin. Oncol. 5:1985–1993.PubMedGoogle Scholar
  16. 16.
    Butler, K., and C. Baker. 1988. Candida: An increasingly important pathogen in the nursery. Pediatr. Clin. N. Amer. 35:543–563.Google Scholar
  17. 17.
    Cassone, A. 1986. Cell wall of pathogenic yeasts and implications for antimycotic therapy. Drugs Exp. Clin. Res. 12:635–643.PubMedGoogle Scholar
  18. 18.
    Centers for Disease Control. 1984. Nosocomial infection surveillance. CDC Surveillance Summary 1983. 33:9–22.Google Scholar
  19. 19.
    Christiansen, K., E. Bernard, J. Gold, and D. Armstrong. 1985. Distribution and activity of amphotericin B in humans. J. Infect. Dis. 152:1037–1043.PubMedCrossRefGoogle Scholar
  20. 20.
    Clemons, K., L. Hanson, A. Perlman, and D. Stevens. 1989. Efficacy of SCH39304 in a systemic model of murine coccidioidomycosis. 31st Intersci. Conf. Antimicrob. Agents Chemother., abstr. 823.Google Scholar
  21. 21.
    DeBono, M., B. J. Abbott, J. Turner, L. Howard, R. Gordee, A. Hunt, M. Barnhart, R. Molloy, K. Willard, D. Fukuda, T. Butler, and D. J. Zeckner. 1988. Synthesis and evaluation of LY121019, a member of a series of semisynthetic analogues of the antifungal lipopeptide echinocandin B. Ann. N.Y. Acad. Sci. 544:152–167.PubMedCrossRefGoogle Scholar
  22. 22.
    Defaveri, J., and J. Graybill. 1989. SCH-39304 in treatment of murine pulmonary aspergillosis. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 822.Google Scholar
  23. 23.
    Defaveri, J., and J. Graybill. 1989. Treatment of chromoblastomycosis with antifungal azotes. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 820.Google Scholar
  24. 24.
    Defaveri, J., S. Sun, and J. Graybill. 1989. Treatment of murine coccidioidal meningitis with SCH39304.29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 824.Google Scholar
  25. 25.
    Denning, D., Tucker, R.M., Hanson, L.H., and D. Stevens. 1989. Treatment of invasive aspergillosis with itraconazole. Am. J. Med. 86:791–800.PubMedCrossRefGoogle Scholar
  26. 26.
    Dick, J.D., B.R. Rosengard, W.G. Merz, R.K. Stuart, G.M. Hutchins, and R. Saral. 1985. Fatal disseminated candidiasis due to amphotericin B-resistant Candida guilliermondii. Ann. Int. Med. 102:67–68.PubMedGoogle Scholar
  27. 27.
    Dismukes, W. 1988. Cryptococcal meningitis in patients with AIDS.J. Infect. Dis. 157:624–628.PubMedCrossRefGoogle Scholar
  28. 27a.
    Dismukes W., G. Cloud, S. Thompson, A. Sugar, C. Tuazon, D. Kaufman, M. Grieco, J. Jacobson, W. Powderly, P. Robinson and A.L. B’ham. 1989. Fluconazole versus amphotericin B therapy of acute cryptococcal meningitis. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1065.Google Scholar
  29. 28.
    Dixon, D., and A. Polak. 1987. In vitro and in vivo studies with three agents of central nervous system phaeohyphomycosis. Chemotherapy 33:129–140.PubMedCrossRefGoogle Scholar
  30. 29.
    Dixon, D.M., T.J. Walsh, W.G. Merz, and M.R. McGinnis 1989 Human central nervous system infections due to Xylohypha bantiana (Cladosporium trichoides). Rev. Infect. Dis. 11:515–525.PubMedCrossRefGoogle Scholar
  31. 30.
    Drutz, D.J., and R. Fetchick. 1988. Fungal infections of the kidney and urinary tract. p. 1015–1047. In R.W. Schrier, C.W. Gottschalle (eds.), Diseases of the kidney, 4th ed. Little, Brown, & Co., Boston.Google Scholar
  32. 31.
    Edwards, J.E. 1985. Candida endophthalmitis, p. 211–225. In: G.P. Bodey, V. Fainstein (eds.), Candidiasis. Raven Press, New York.Google Scholar
  33. 32.
    Eisenberg, E.S., I. Leviton, and R. Soeiro. 1986. Fungal peritonitis in patients receiving peritoneal dialysis: Experience with 11 patients and review of the literature. Rev. Infect. Dis. 8:309–321.PubMedCrossRefGoogle Scholar
  34. 33.
    Eng. R., E. Bishburg, S. Smith, and R. Kapila. 1986. Cryptoccocal infections in patients with acquired immune deficiency syndrome. Am. J. Med. 81:19–23.Google Scholar
  35. 34.
    Eras, P., M.J. Goldstein, and P. Sherlock. 1972. Candida infection of the gastrointestinal tract. Medicine 51:367–379.PubMedCrossRefGoogle Scholar
  36. 35.
    Fader, R.C., and M.R. McGinnis. 1988. Infections caused by dematiaceous fungi: chromoblastomycosis and phaeohyphomycosis. Infect. Dis. Clin. N. Amer. 2:925–938.Google Scholar
  37. 36.
    Franklyn, K.M., J.R. Warmington, A.K. Ott, and R.B. Ashman. 1990. An immunodominant antigen of Candida albicans shows homology to the enzyme enolase. Immunol. Cell. Biol. 68:173–178.PubMedCrossRefGoogle Scholar
  38. 37.
    Fromtling, R. 1988. Overview of medically important antifungal azole derivatives. Clin. Microb. Rev. 1:187–217.Google Scholar
  39. 38.
    Fromtling, R.A., and G.K. Abruzzo. 1989. L-671,329, a new antifungal agent. In vitro activity, toxicity, and efficacy in comparison to aculeacin. J. Antibiot. 42:174–178.PubMedCrossRefGoogle Scholar
  40. 39.
    Gold, J.W.M., B. Wong, E.M. Bernard, T.E. Kiehn, and D. Armstrong. 1983. Serum arabinitol concentrations and arabinitol/creatinine ratios in invasive candidiasis. J. Infect. Dis. 147:504–513.PubMedCrossRefGoogle Scholar
  41. 40.
    Gordee, R.S., D.J. Zeckner, L.F. Ellis, A.L. Thakker, and L.C. Howard. 1984. In vitro and in vivo anti-candida activity and toxicology of LY121019. Ann. N.Y. Acad. Sci. 37:1054–1065.Google Scholar
  42. 41.
    Graybill, J. 1988. Systemic fungal infections diagnosis and treatment I: Therapeutic agents. Infect. Dis. Clin. N. Amer. 2:805–825.Google Scholar
  43. 42.
    Group, Internat. Antimicrob. Ther. E.O.R.T.C. 1989. Empiric antifungal therapy in febrile granulocytopenic patients. Am. J. Med. 86:668–672.CrossRefGoogle Scholar
  44. 43.
    Guinet, R.J., A. Chanas, G. Goullier, P. Bonnefoy, and Ambroise-Thomas. 1983. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. J. Clin. Microbiol. 18:443–444.PubMedGoogle Scholar
  45. 44.
    Hay, R., B. DuPont, and J. Graybill. 1987. First international symposium on itraconazole. Rev. Infect. Dis. 9 (suppl.):1–152.CrossRefGoogle Scholar
  46. 45.
    Hector, R. 1990. Evaluation of nikkomycins and Z in murine models of Coccidioidomycosis , Histoplasmosis , and Blastomycosis. Antimicrob. Agents Chemother. 34:587–593.PubMedCrossRefGoogle Scholar
  47. 46.
    Hobbs, M., J.R. Perfect, and D. Durack. 1988. Evaluation of in vitro antifungal activity of LY121019. Euro. J. Microbiol. Infect. Dis. 7:77–80.CrossRefGoogle Scholar
  48. 47.
    Hoeprich, P. 1989. Chemotherapy for systemic mycoses. p. 317–351. In Tucker (ed.), Progress in drug research, vol. 33. Billehauser, Basel.CrossRefGoogle Scholar
  49. 48.
    Johnston, P., J. Lee, M. Demanski, F. Dressler, E. Tucker, M. Rothenberg, P. Pizzo, and T. Walsh. 1991. Late recurrent Candida endocarditis. Chest, in press.Google Scholar
  50. 49.
    Jones, J.M. 1980. Kinetics of antibody responses to cell wall mannan and a major cytoplasmic antigen of Candida albicans in rabbits and humans. J. Lab. Clin. Med. 96:845–860.PubMedGoogle Scholar
  51. 50.
    Karp, J., P. Burch, and W.G. Merz. 1988. An approach to intensive antileukemia therapy in patients with previous invasive aspergillosis. Am. J. Med. 85:203–206.PubMedCrossRefGoogle Scholar
  52. 50a.
    Knoper, S.R., and J.N. Galgiani. 1988. Coccidioidomycosis. Infect. Dis. Clin. N. Amer. 2:861–875.Google Scholar
  53. 51.
    Kovacs, J., A. Kovacs, M. Polis, W. Wright, V. Gill, C. Tuazon, E. Gelmann, H. Lane, R. Lonfield, G. Overturf, A. Macher, A. Fauci, J. Parrillo, J. Bennett, and H. Masur. 1985. Cryptococcosis in the acquired immunodeficiency syndrome. Ann. Int. Med. 103:533–538.PubMedGoogle Scholar
  54. 52.
    Larsen, R., and M. Leal. 1989. Fluconazole compared to amphotericin B as treatment of cryptococcal meningitis. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1062.Google Scholar
  55. 53.
    Lecciones, J., P. Kelly, J. Lee, R. Schaufele, P. Pizzo, and T. Walsh. 1989. In vitro activity of LY 121019 alone and in combination with other antifungal agents against C. albicans and T. glabra ta, F3, p. 458. Abstr. 89th Annual Meeting of the Amer. Soc. Microbiol.Google Scholar
  56. 54.
    Lee, J., P. Kelly, J. Lecciones, D. Coleman, R. Gordee, P. Pizzo, and T. Walsh. 1990. Cilofungin (LY121019) shows non-linear plasma pharmacokinetics and tissue penetration in rabbits. Antimicrob. Agents Chemother. 34:2240–2245.PubMedCrossRefGoogle Scholar
  57. 55.
    Lee, J.W., C. Lin, D. Loebenberg, M. Rubin, P.A. Pizzo, and T.J. Walsh. 1989. Pharmacokinetics and tissue penetration of Sch 39304 in granulocytopenic and nongranulocytopenic rabbits. Antimicrob. Agents Chemother. 33:1932–1935.PubMedCrossRefGoogle Scholar
  58. 56.
    Lemieux, C., G. St. Germain, J. Vincelette, L. Kaufman, and L. DeRepentigny. 1990. Collaborative evaluation of antigen detection by a commercial latex agglutination test and enzyme immunoassay in the diagnosis of invasive candidiasis. J. Clin. Microbiol. 28:249–253.PubMedGoogle Scholar
  59. 57.
    Levitz, S. 1989. Aspergillosis. Infect. Dis. Clin. N. Amer. 3:1–18.Google Scholar
  60. 57a.
    Lief, M., and F. Sarfarazi. 1986. Prostatic cryptococcosis in acquired immune deficiency syndrome. Urology 28:318–319.PubMedCrossRefGoogle Scholar
  61. 58.
    Loebenberg, D., R. Parmegiani, E. Moss, D. Frank, M. McHugh, T. YaroshTomaine, B. Antonacci, F. Menzel, R.S. Hare, and G.H. Miller. 1989. SCH39304, a new antifungal agent. Oral activity in a murine model of pulmonary aspergillosis. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 821.Google Scholar
  62. 59.
    Lopez-Bernstein, G. 1986. Liposomal amphotericin B in the treatment of fungal infections. Ann. Int. Med. 105:130–131.Google Scholar
  63. 60.
    Lopez-Bernstein, G., G. Bodey, L. Frankel, and K. Mehta. 1987. Treatment of hepatosplenic candidiaisis with liposomal amphotericin B.J. Clin. Oncol. 5:310–317.Google Scholar
  64. 61.
    Macher, A.M., M.L. De Vinatea, S.M. Tuur, and P. Angritt. 1988. AIDS and the mycoses. Infect. Dis. Clin. N. Amer. 2:827–839.Google Scholar
  65. 62.
    Marsh, P.K., F.P. Tally, J. Kellum, A. Callow, and S.L. Gorbach. 1982. Candida infections in surgical patients. Ann. Surg. 198:42–47.CrossRefGoogle Scholar
  66. 63.
    Mason, A.B., M.E. Brandt and H.R. Buckley. 1988. Enolase activity associated with a C. albicans cytoplasmic antigen. Yeast 5:5231–5240.Google Scholar
  67. 64.
    Matthews, R., and J. Burnie. 1988. Diagnosis of systemic candidiasis by an enzyme-linked dot immunobinding assay for a circulating immunodominant 47-kilodalton antigen. J. Clin. Microbiol. 26:459–463.PubMedGoogle Scholar
  68. 65.
    Matthews, R.C., J.P. Burnie, and S. Tabaqchali. 1987. Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J. Clin. Microbiol. 25:230–237.PubMedGoogle Scholar
  69. 66.
    McLeod, R., and J.S. Remington. 1977. Postoperative fungal endocarditis. p. 163–236. In R.J. Duma (ed.), Infections of prosthetic heart valves and vascular grafts. University Park Press, Baltimore, MD.Google Scholar
  70. 67.
    Melchinger, W., and J. Mueller. 1987. Studies of the in vitro sensitivity of yeast strains isolated from clinical specimens to LY121019, a new antifungal agent. Mykosen 30:605–608.PubMedCrossRefGoogle Scholar
  71. 67a.
    Merz, W.G., J. Karp, and M. Hoagland. 1988. Diagnosis and successful treatment of fusariosis in the compromised host. J. Infect. Dis. 158:1046–1055.PubMedCrossRefGoogle Scholar
  72. 68.
    Meunier, F., L. Leleux, J. Gerain, D. Ninove, R. Snoeck, and J. Klastersky. 1987. Prophylaxis of aspergillosis in neutropenic cancer patients with nasal spray of amphotericin B: a prospective randomized study. 27th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1346.Google Scholar
  73. 69.
    Meunier, F., L. Sculier, P. Van Der Auwera, and M. Aoun. 1989. Therapy with amphotericin B (AmB) in phospholipid vesicles (VS104) for proven or suspected aspergillosis in patients with hematological malignancies. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 114.Google Scholar
  74. 70.
    Meunier-Carpentier, F. 1984. Chemoprophylaxis of fungal infections. Am. J. Med. 76:652–656.PubMedCrossRefGoogle Scholar
  75. 71.
    Morstyn, G., L. Campbell, L. Souza, M. Alton, N. Keech, J. Keech, M. Green, W. Scheridan, D. Metcalf, and R. Fox. 1988. Effect of granulocyte colony stimulating factor on neutropenia induced by cytotoxic chemotherapy. Lancet 2:667–672.CrossRefGoogle Scholar
  76. 72.
    Odds, F.C. 1988. Activity of cilofungin (LY121019) against Candida species in vitro. J. Antimicrob. Chemother. 22:891–897.PubMedCrossRefGoogle Scholar
  77. 73.
    Oki, T., M. Kakushima, M. Nishio, H. Kamei, S.M. Hirano, Y. Sawada, and M. Konishi. 1990. BMY-28864, a water soluble pradimicin derivative. 30th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 592.Google Scholar
  78. 74.
    Panos, R.J., L.F. Barr, T.J. Walsh, and H.J. Silverman. 1988. Factors associated with fatal hemoptysis in cancer patients. Chest 94:1008–1013.PubMedCrossRefGoogle Scholar
  79. 75.
    Pappagianis, D., M.S. Collins, R. Hector, and J. Remington. 1979. Development of resistance to in Candida lusitaniae infection in a human. Antimicrob. Agents Chemother. 16:123–126.PubMedCrossRefGoogle Scholar
  80. 76.
    Perfect, J.R., K.A. Wright, M.M. Hobbs, and D.T. Durack. 1989. Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH 39304. Antimicrob. Agents Chemother. 33:1735–1740.CrossRefGoogle Scholar
  81. 77.
    Petranyi, G., A. Stutz, N. Ryder, J. Meingasner, and H. Mieth. 1987. Experimental antimycotic activity of naftifine and terbinafine, p. 441–459. In R.A. Fromtling (ed.), Recent trends in the discovery, development, and evaluation of antifungal agents. J.R. Prous Science Publishers, Barcelona, Spain.Google Scholar
  82. 78.
    Pfaller, M.A., S.S. Wey, T. Gerarden, A. Houston, and R.P. Wenzel. 1989. Susceptibility of nosocomial isolates of Candida species to LY121019 and other antifungal agents. Diagn. Microbiol. Infect. Dis. 12:1–14.PubMedCrossRefGoogle Scholar
  83. 79.
    Pizzo, P.A., K. Robichaud, F.A. Gill, and F.G. Witebsky. 1982. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am. J. Med. 72:101–110.PubMedCrossRefGoogle Scholar
  84. 80.
    Polak, A., and D. Dixon. 1987. Antifungal activity of amorolfine (Ro 14–4767/002) in vitro and in vivo, p. 555–573. In R.A. Fromtling (ed.), Recent trends in the discovery, development, and evaluation of antifungal agents. J.R. Prous Science Publishers, Barcelona, Spain.Google Scholar
  85. 81.
    Powderly, W.G., G. S. Kobayashi, G. P. Herzig, and G. Medoff. 1988. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am. J. Med. 84:826–832.PubMedCrossRefGoogle Scholar
  86. 82.
    Quintiliani, R., N. Owens, R. Quercia, J. Klimek, and C. Nightingale. 1984. Treatment and prevention of oropharyngeal candidiasis. Am. J. Med. 77:44–48.PubMedGoogle Scholar
  87. 83.
    Rinaldi, M.G. 1989. Zygomycosis. Infect. Dis. Clin. N. Amer. 3:19–41.Google Scholar
  88. 84.
    Ringel, S. 1987. Ambruticin: a unique oral antibiotic, p. 585–593. In R.A. Fromtling (ed.), Recent trends in the discovery, development, and evaluation of antifungal agents. J.R. Prous Science Publishers, Barcelona, Spain.Google Scholar
  89. 85.
    Rippon, J.W. 1988. Pseudallescheriasis, p. 651–680. In J.W. Rippon (ed.), Medical mycology: the pathogenic fungi and pathogenic Actinomycetes. W.B. Saunders, Philadelphia, PA.Google Scholar
  90. 86.
    Roberts, C. 1984. Coccidioidomycosis in acquired immune deficiency syndrome. Depressed humoral as well as cellular immunity. Am. J. Med. 76:734.PubMedCrossRefGoogle Scholar
  91. 87.
    Roy, J.B., J.R. Gejer, and J.A. Ohr. 1984. Urinary tract candidiasis. An Update. Urology. 23:533–537.PubMedCrossRefGoogle Scholar
  92. 88.
    Saag, M. and W. Dismukes. 1988. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32:1–8.PubMedCrossRefGoogle Scholar
  93. 89.
    Sanford, G., W. Merz, J. Wingard, P. Charache, and R. Saral. 1980. The value of fungal surveillance cultures as predictors of systemic fungal infections. J. Infect. Dis. 142:503–509.CrossRefGoogle Scholar
  94. 90.
    Schechtman, S., L. Fumaro, T. Robin, E. Bottone, and J. Cuttner. 1984. Clotrimazole treatment of oral candidiasis in patients with neoplastic disease. Am. J. Med. 76:91–94.CrossRefGoogle Scholar
  95. 91.
    Sawada, Y., M. Nishio, M. Hatori, H. Yamamoto, M. Kakushima, M. Hirano, T. Miyaki, M. Konishi, and T. Oki. Pradimicins D, E, FA-1, and FA-2, novel antifungal antibiotics. Production, chemistry, and biological activities. 30th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 591.Google Scholar
  96. 91a.
    Schmatz, D.M., M.A. Romancheck, L.A. Pittarelli, R.E. Schwartz, R.A. Fromtling, K.H. Nollstadt, F.L. Vanmiddlesworth, K.E. Wilson, and M.J. Turner. 1990. Treatment of Pneumocystis carinii pneumonia with 1,3-β-glucan synthesis inhibitors. Proc. Natl. Acad. Sci. USA 87:5950–5954.PubMedCrossRefGoogle Scholar
  97. 92.
    Schmitt, H., E. Bernard, J. Adrade, and et al. 1987. Inhibitory and cidal activity of terbinafine versus Aspergillus. Antimicrob. Agents Chemother. 32:780–781.CrossRefGoogle Scholar
  98. 93.
    Schmitt, H., E. Bernard, M. Hauser, and D. Armstrong. 1988. Aerosol amphotericin B for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 32:1676–1679.PubMedCrossRefGoogle Scholar
  99. 94.
    Selik, R., E. Starcher, and J. Curran. 1987. Opportunistic diseases reported in AIDS patients: frequencies, associations, and trends. AIDS. 1:175–182.PubMedGoogle Scholar
  100. 95.
    Solomkin, J., A. Flohr, and R. Simmons. 1982. Indications for therapy for fungemia in postoperative patients. Arch. Surg. 117:1272–1275.PubMedCrossRefGoogle Scholar
  101. 96.
    Solomon, S.L., R.F. Khabbaazz, R.H. Parker, R.L. Anderson, M.A. Geraghty, R.M. Furman, and W.J. Martone. 1984. An outbreak of Candida parapsilosis bloodstream infections in patients receiving parenteral nutrition. J. Infect. Dis. 149:98–107.PubMedCrossRefGoogle Scholar
  102. 97.
    Spitzer, E.D., S.J. Travis, and G.S. Kobayashi. 1988. Comparative in vitro activity of LY121019 and amphotericin B against clinical isolates of Candida species. Europ. J. Clin. Microbiol. Infect. Dis. 7:80–81.PubMedCrossRefGoogle Scholar
  103. 98.
    Stein, D., and A. Sugar. 1989. Fungal infections in the immunocompromised host. Diagn. Microbiol. Infect. Dis. 12 (Suppl.):221–228.CrossRefGoogle Scholar
  104. 99.
    Strinden, W.D., R.B. Helgerson, and D.B. Maki, 1985. Candida septic thrombosis of the great vein associated with central catheters. Ann. Surg. 202:653–658.PubMedCrossRefGoogle Scholar
  105. 100.
    Strockbine, N.A., M.T. Largen, and H.R. Buckley. 1984. Production and charactrization of three monoclonal antibodies to Candida albicans proteins. Infect. Immun. 43:1012–1018.PubMedGoogle Scholar
  106. 101.
    Strockbine, N.A., M.T. Largen, S.M. Zweibel, and H.R. Buckley. 1984. Identification and molecular weight characterization of antigens from Candida albicans that are recognized by human sera. Infect. Immun. 43:715–721.PubMedGoogle Scholar
  107. 102.
    Sugar, A., and C. Saunders. 1989. Oral fluconazole as suppressive therapy of disseminated cryptococcosis in patients with acquire immune deficiency syndrome. Am. J. Med. 85:481–489.CrossRefGoogle Scholar
  108. 103.
    Sugar, A., M. Picard, and L. Noble. 1989. Comparison of SCH 39304, fluconazole, and amphotericin B in the treatment of murine pulmonary blastomycosis. 29th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 825.Google Scholar
  109. 104.
    Symposium. 1990. Fluconazole: a novel advance in therapy for systemic fungal infections. Rev. Infect. Dis. 12:S263–S389.CrossRefGoogle Scholar
  110. 105.
    Taft, C.S., and C.P. Selitrenikoff. 1988. LY121019 inhibits Neurospora crassa growth and (1–3)-β-D-glucan synthetase. J. Antibiot. 41:697–701.PubMedCrossRefGoogle Scholar
  111. 105a.
    Takeuchi, T., T. Hara, M. Hamada, H. Yamamoto, S. Gomi, Y. Orikasa, M. Sezaki, S. Kondo, and H. Yamaguchi. 1988. Benanomicins A and B, novel antifungal antibiotics. 28th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 1007.Google Scholar
  112. 106.
    Tavitian, A., J. Raufman, L. Rosenthal, J. Weber, C. Webber, and H. Dincsoy. 1986. Ketoconazole-resistant Candida esophagitis in patients with acquired immunodeficiency syndrome. Gastroenterol. 90:443–445.Google Scholar
  113. 107.
    Thaler, M., B. Pastakia, and T. Shawker. 1988. Hepatic candidiasis in cancer patients: the evolving picture of the syndrome. Ann. Int. Med. 108:88–100.PubMedGoogle Scholar
  114. 108.
    Tollemar, J., O. O11e Ringden, and G. Tyden. 1990. Liposomal amphotericin B (AmBisome) treatment in solid organ and bone marrow transplant recipients. Efficacy and safety evaluation. Clin. Transplantation. 4:167–175.Google Scholar
  115. 109.
    Vilars, V., and J. TC. 1988. The clinical profile of terbinafine: a new topical and systemic fungicidal drug for the treatment of dermatomycoses, p. 231–234. In J.M. Torres-Rodriguez (ed.), 10th Congress of the International Society for Human and Animal Mycology-ISHAM.J.R. Prous Science Publishers, Barcelona, Spain.Google Scholar
  116. 110.
    Walsh, T., and D. Dixon. 1989. Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment. Eur. J. Epidemiol. 5:131–142.PubMedCrossRefGoogle Scholar
  117. 111.
    Walsh, T., and W. Gray. 1987. Candida epiglottitis in immunocompromised patients. Chest 91:482–485.PubMedCrossRefGoogle Scholar
  118. 112.
    Walsh, T., S. Hamilton, and N. Belitsos. 1988. Esophageal candidiasis. Diagnosis and treatment of an increasingly recognized fungal infection. Postgrad. Med. 84:193–205.PubMedGoogle Scholar
  119. 113.
    Walsh, T., and P. Pizzo. 1988. Nosocomial fungal infections: a classification for hospital-acquired fungal infections and mycoses arising from endogenous flora or reactivation. Ann. Rev. Microbiol. 42:517–545.CrossRefGoogle Scholar
  120. 114.
    Walsh, T., and P. Pizzo. 1988. Treatment of systemic fungal infections: recent advances and current problems. Eur. J. Clin. Microbiol. 7:460–475.CrossRefGoogle Scholar
  121. 115.
    Walsh, T.J. 1989. Trichosporonosis. Medicine 3:43–65.Google Scholar
  122. 116.
    Walsh, T.J. 1990. Invasive pulmonary aspergillosis in patients with neoplastic diseases. Seminars Resp. Infect. 5:111–122.Google Scholar
  123. 117.
    Walsh, T.J., C. Bustamente, D. Vlahov, and H.C. Standiford. 1986. Candida suppurative peripheral thrombophlebitis: prevention, recognition and management. Infect. Control. 7:16–22.PubMedGoogle Scholar
  124. 118.
    Walsh, T.J., and K. Butler. 1990. Fungal infections complicating pediatric AIDS, p. 225–244. In P.A. Pizzo, and C. Wilfert (eds.), Pediatric AIDS. Williams and Wilkins, Baltimore.Google Scholar
  125. 119.
    Walsh, T.J., H. Buckley, M. Hom-Eng, D.E. Johnson, M. Maret, and P. Gary. 1988. Analysis of a 48-kilodalton cytoplasmic antigen of Candida albicans in experimental candidiasis, 0–111, p. 119. Abstr. 10th Congress of the International Society for Human and Animal Mycology. Barcelona, 1988.Google Scholar
  126. 120.
    Walsh, T.J., L.R. Caplan, and D.B. Hier. 1985. Aspergillus infections of the central nervous system: a clinicopathological analysis. Ann. Neurology 18:574–582.CrossRefGoogle Scholar
  127. 121.
    Walsh, T.J., P.F. Jarosinski, and R.A. Fromtling. 1990. Increasing usage of systemic antifungal agents. Diagn. Microbiol. Infect. Dis. 13:37–40.PubMedCrossRefGoogle Scholar
  128. 122.
    Walsh, T.J., J. Lee, J. Lecciones, P. Kelly, J. Peter, V. Thomas, J. Bacher, and P.A. Pizzo. 1990. Sch 39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits. Antimicrob. Agents Chemother. 34:1560–11564.PubMedCrossRefGoogle Scholar
  129. 122a.
    Walsh, T.J., C.L. Lester-McCully, M.G. Rinaldi, J.E. Wallace, F.M. Balis, J.W. Lee, P.A. Pizzo, and D.G. Poplack. 1990. Penetration of SCH-39304, a new antifungal triazole, into cerebrospinal fluid of primates. Antimicrob. Agents Che-mother. 34:1281–1284.CrossRefGoogle Scholar
  130. 123.
    Walsh, T.J., G. Melcher, M. Rinaldi, J. Lecciones, D. McGough, J. Lee, D. Callender, M. Rubin, and P.A. Pizzo. 1990. Trichosporon beigelii: an emerging pathogen resistant to amphotericin B..i. Clin. Microbiol. 28:1616–1622.PubMedGoogle Scholar
  131. 124.
    Walsh, T.J., and W.G. Merz. 1986. Pathologic features in the human alimentary tract associated with invasiveness of Candida tropicalis. Am. J. Clin. Pathol. 85:498–502.PubMedGoogle Scholar
  132. 125.
    Wheat, L. 1988. Histoplasmosis. Infect. Dis. Clin. N. Amer. 2:841–860.Google Scholar
  133. 125a.
    Wheat, L., T. Slama, and M. Zeckel. 1985. Histoplasmosis in the acquired immune deficiency syndrome. Am. J. Med. 78:203–210.PubMedCrossRefGoogle Scholar
  134. 126.
    Wingard, J.R., W.G. Merz, and R. Saral. 1979. Candida tropicalis: a major pathogen in immunocompromised patients. Ann. Int. Med. 91:539–543.PubMedGoogle Scholar
  135. 127.
    Wong, B., and K.L. Brauer. 1988. Enantioselective measurement of fungal Darabinitol in the sera of normal adults and patients with candidiasis. J. Clin. Microbiol. 26:1670–1674.PubMedGoogle Scholar
  136. 128.
    Zuger, A., E. Louis, R. Holzman, M. Simberkoff, and J. Rahal. 1986. Cryptococcal disease in patients with the acquired immunodeficiency syndrome. Diagnostic features and outcome of treatment. Ann. Int. Med. 104:234–240.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • Thomas J. Walsh

There are no affiliations available

Personalised recommendations